Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06637904

TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections

A pre/post interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and/or the staging area/fast track area) with suspected infection and tachycardia or fever will be enrolled. Study conduct will be performed under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA). Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching, whereas participants in the post-phase will be managed incorporating the TriVerity™ Acute Infection and Sepsis Test results with standardized guidance for interpretation and resulting management actions. Many outcomes will be captured and compared between the pre- and post-phase phases including sepsis bundle compliance, patient disposition, appropriate use of antimicrobials (antibiotics and antivirals) and health economic findings. Safety measures for participants in the post-phase will include patient follow-up at predefined time points. The objective is to demonstrate improvement of patient management when incorporating the TriVerity Test result compared to standard of care. Improvements based on diagnostic (bacterial vs viral vs non-infectious inflammation) and prognostic (need for 7-day ICU level care) readouts of the TriVerity Test result will be tracked.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sepsis Arrhythmias, Cardiac Body Temperature Changes Cardiac Conduction System Disease Cardiovascular Diseases Fever Heart Diseases Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Systemic Inflammatory Response Syndrome Tachycardia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

OSF HealthCare Saint Francis Medical Center, Peoria, Illinois, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Participant presents to ED with ALL of the below:

2.1. Suspected acute infection (e.g., respiratory, urinary, abdominal, skin & soft-tissue infection, meningitis/encephalitis, or any other infection), and 2.2. Either heart rate >100 beats per minute or/and temperature >38C. 2.3. NOT immediately roomed in a primary designated treatment location,( i.e., they can be in the waiting room, ED triage hallways, and/or ED staging area/fast track area).

  • Able to provide informed consent, or consent by legally authorized representative.
  • Reachable via confirmed working cell phone (with backup contact number) and willing to respond to follow-up safety checks (see below for details).

Exclusion criteria

  • Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to presentation in the waiting room of the ED. Participants will not be excluded for use of:
  • Antiviral treatment for chronic viral infections, i.e., HIV, hepatitis B and hepatitis C
  • Topical antibiotics, topical antivirals or topical antifungal agents
  • Anti-herpes prophylaxis aiding suppression of a recuring herpes infection
  • Single dose of one or combination of peri-operative (prophylactic) antibiotics
  • Patients receiving palliative or hospice care, or those receiving limited interventional care (see Appendix B).
  • Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient.
  • Participants receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. Participants that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial.
  • Participants previously enrolled in the present clinical trial.

Treatment and study plan

TriVerity Test

Diagnostic Test

Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.

Primary outcomes

  1. SEP-1 bundle compliance

    Time frame: Within 72 hours of ED admission

    Mandatory hospital procedures for patients admitted with suspected sepsis

  2. Time to final ED disposition order

    Time frame: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

    Time from Triage (on Day 0) to the Time the ED physician orders the subject disposition (i.e., where the subject will go next: admittance or discharge).

Secondary outcomes

  1. Percent of patients with antibiotics given in the ED combined with noninferior safety outcomes

    Time frame: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

    Calculated based on number of patients given antibiotics in ED

  2. Emergency Department LOS

    Time frame: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

    Length of Stay

  3. Diagnostic ordering practices

    Time frame: Date of enrollment (Day 0) to 72 hours

    Capturing the diagnostic ordering practices of attending physician (comparing physician choices and decisions before and after the TriVerity Test)

  4. Hospital admission rates

    Time frame: Date of enrollment (Day 0) to 72 hours

    Overall admission rates for patients that meet study criteria from emergency department to other location (e.g., ICU)

  5. Total hospital costs

    Time frame: Date of enrollment (Day 0) to 28 days

    Overall hospital costs for patients that meet study criteria

Study contacts

Contact information is provided by the study sponsor or research team.

Shailee Rasania

CONTACT

[email protected]

862-295-8740

Sponsors and collaborators

Lead sponsor

Inflammatix

Industry

Registry information

Acronym: TIMED

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 15, 2024
Registry last updated
Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.